Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10504 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 May 2026 According to a Hansoh Pharmaceutical media release, HS-10504 received Breakthrough-Therapy-Designation by the National Medical Products Administration (NMPA) of China for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the EGFR C797S mutation after prior EGFR-TKI therapy failure.
21 May 2026 Results presented in the Hansoh Pharmaceutical media release.
17 Sep 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com